BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240312
DTEND;VALUE=DATE:20240316
DTSTAMP:20260516T000618
CREATED:20231215T122622Z
LAST-MODIFIED:20231215T124912Z
UID:38363-1710201600-1710547199@www.pharmajournalist.com
SUMMARY:14th World ADC London 2024
DESCRIPTION:We find ourselves at the cutting edge of oncology innovation\, with the ADC field booming with excitement due to the constant eflux of clinical progress and a plethora of high-value collaborations. \nAs such the 14th World ADC London 2024 returns this March as a crucial touchpoint for all antibody drug conjugate developers across Europe. \nThis meeting is the place where innovation meets collaboration to drive antibody-drug conjugates forward and transform cancer therapy as we know it. Uniting 600+ industry experts and ADC newcomers\, this is a conversation you can’t afford to miss. \nTake a look at the full agenda here. \nEmbark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation\, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle. \nHere are some of the leading minds sharing translatable lessons to advance your pipeline including: \n\nAstrid Clarke\, Director\, Head of Early-Stage IND to Medicine Research\,Seagen\nColm Reddington\, Director- Global Regulatory\, Chemistry\, Manufacturing & Control\, AstraZeneca\nDaniel Milano\, Senior Director\, Process Development\, ImmunoGen\nDhiraj Gambhire\, Executive Director – Global Clinical Lead\, Enhertu\, Breast & Medical\, Daiichi Sankyo\nEmmett Scmidtt\, Vice President\, Lead External- Collaborations Project Team Global Clinical Development\, Merck & Co\nGerold Meindhart\, Vice President\, Asset & Portfolio Management\, Daiichi Sankyo\nIan Andrews\, Senior Manager\, Strategic External Development\, GlaxoSmithKline\nKurt Pike\, Senior Director\, External Innovation\, Janssen\nLarisa Stone\, Clinical Development Director\, Gilead\nLolke deHaan\, Vice President\, Toxicology\, ADC Therapeutics\nMike Liao\, Global Clinical Pharmacology Lead\, Genentech\nVenkatesh Pilla Reddy\, Senior Director\, Global PKPD & Pharmacometrics\, Eli Lilly\n\nSee the full speaker faculty and session details here. \nWhether you are pioneering ADC discoveries\, accelerating your conjugate through preclinical and clinical development\, or optimising your CMC efforts\, this is your chance to ahead of the curve with the high-quality and invaluable guidance of the supportive ADC community.
URL:http://www.pharmajournalist.com/event/14th-world-adc-london-2024/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
END:VCALENDAR